TAIZHOU, China, March 8, 2021 /PRNewswire/ -- At 19:20 on
March 4, 2021 (Beijing time), the results of the 2021 EFQM
Global Award were announced. Yangtze River Pharmaceutical (Group)
Co., Ltd. from China was on
the list, which represents that its quality management level has
been aligned with that of world-class companies, and has won
praises from the world for "Made in China".
"Applying for the EFQM Global Award is a fusion of Chinese
culture and European culture, a bridge connecting Chinese quality
and European quality, and a mutual learning between Chinese
management model and EFQM model. We will continue to promote the
application of the EFQM model to serve the health of all
mankind," Mr. Xu Jingren, chairman
of Yangtze River Pharmaceutical Group, said.
A total of 12 organizations
around the world have won the 2021 EFQM Global Award, and 2,200
people from 94 countries participated in the ceremony online. This
is the first pharmaceutical company in the world to win the award
after the promotion and implementation of the new EFQM model in
2019. Its CEO, Li Sen, attended
online and addressed on behalf of the company.
The EFQM Global Award is one of the three major quality awards
in the world, and is as famous as the Baldrige National Quality
Award and the Deming Prize. In 1991, it was initiated by the
Vice-President of the European Commission, Martin Bengeman, jointly
initiated by the European Commission, the European Organization for
Quality (EOQ) and the European Foundation for Quality Management
(EFQM), and awarded once a year. It is for every high-performance
organization in the world, focusing on the recognition of
performance excellence companies and helping all applicants pursue
excellence. The EFQM Global Award uses the EFQM model to
systematically evaluate the applicants. EFQM organized a survey and
research of nearly 2,000 change experts, held 24 internal seminars,
and had face-to-face exchanges with leaders of more than 60
different organizations. A core team composed of experts from
different industries and academia was formed to define a new
version of the EFQM model, which was transformed from an assessment
tool into an important management framework and methodology,
including three aspects (direction, execution, and results), seven
criteria, and 30 sub-standards, paying more attention to ecosystem,
circular economy, transformation and sustainable development.
Yangtze River Pharmaceutical (Group) Co., Ltd. has participated
in the training and introduced the new EFQM model since
April 2020, then submitted the EFQM
Global Award application in November and successfully passed the
document review. In January this year, an assessment team of 8
experts from different countries conducted an on-site assessment of
the company. Affected by COVID-19, this assessment was conducted by
a combination of site visit and online interviews. In the 5-day
on-site assessment, in addition to the opening meeting, closing
meeting and 4 mirror meetings, the assessors held 34 interviews for
employees at all levels of the company, proposed 552 interview
topics and interviewed 277 employees regarding the development and
implementation of strategies, challenges and opportunities,
organizational culture, changes, ecosystem and interactions with
stakeholders. The assessment team pointed out in the feedback
report that Yangtze River Pharmaceutical (Group) Co., Ltd. has
established a distinctive development concept, and its quality
culture of "Manufacture Medicines for Parents, Manufacture
Medicines for Relatives" and the corporate mission of "Commit for
Better, Dedicate for Caring All" have been deeply rooted in the
hearts of the people, and provide many best practices for industry
development. The assessment team unanimously affirmed the company's
management strengths in six aspects: quality risk control mode and
quality culture, value creation, customer engagement, leading its
ecosystem, leading in the field of traditional Chinese medicine,
and strong business performance.
In the context of the signing of the China-EU Comprehensive
Agreement on Investment (CAI), it is of special significance to
apply for this award. In the future, Yangtze River Pharmaceutical
Group will continue to benchmark advanced international management
concepts, strengthen international exchanges and learning, and
promote high-quality and sustainable development of the
company.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/yangtze-river-pharmaceutical-group-co-ltd-won-the-2021-efqm-global-award-301242881.html
SOURCE Yangtze River Pharmaceutical Group